Analysis and Perspectives

Nov 29, 2024

The evolving landscape of NSCLC treatment presents significant market opportunities for pharmaceutical companies to secure their place.

Nov 20, 2024

Despite decades of research, treatment options are limited in the ARDS market. There are only a few treatments available in the ARDS market. The mainstay of management remains supportive care with mechanical ventilation. Other ARDS treatment options for patients include supplemental oxygen, prone positioning, the u...

Nov 20, 2024

As no approved drug in the ARDS market, uptake of emerging therapies is expected to be high. Currently, several assets are in the ARDS pipeline.

Nov 20, 2024

Acute respiratory distress syndrome (ARDS) prevalence is increasing drastically owing to certain factors such as pneumonia, COVID-19, sepsis,

Nov 08, 2024

It is estimated that the cervical cancer treatment space will experience significant changes during the forecast period of 2024–2034. The future is brighter for patients with cervical cancer. Targeted agents and biomarker-driven therapies hold promise for improved outcomes both as single agents and combinations.

Nov 08, 2024

The HPV vaccine protects against several types of HPV that can cause different types of cancers, which mainly include cervical cancer

Oct 18, 2024

The dynamics of the schizophrenia treatment market is expected to change in future. Key companies are evaluating lead assets to improve treatment space.

Oct 10, 2024

The GBM market size in the 7MM following the launch of a few of many emerging therapies is likely to reach 1,083 million by 2023.

Sep 30, 2024

Pompe Disease Therapeutics market is evolving immensely with the active participation of key companies such as Sanofi, Actus, Amicus

Aug 23, 2024

Several pharmaceutical companies are developing a gene therapy that will positively impact the Duchenne Muscular Dystrophy Treatment Market